• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats.

作者信息

Yang X P, Liu Y H, Scicli G M, Webb C R, Carretero O A

机构信息

Department of Medicine, Henry Ford Hospital, Detroit, Mich 48202, USA.

出版信息

Hypertension. 1997 Sep;30(3 Pt 2):735-40. doi: 10.1161/01.hyp.30.3.735.

DOI:10.1161/01.hyp.30.3.735
PMID:9323015
Abstract

Kinins acting on the B2 receptor appear to be involved in the cardioprotective effect of preconditioning on myocardial ischemia/reperfusion injury. We tested the hypothesis that in mice lacking the gene encoding for the B2 kinin receptor (B2 knockout mice; B2-KO) as well as in rats deficient in high-molecular-weight (HMW) kininogen (Brown Norway Katholiek rats; BNK), the cardioprotective effect of preconditioning is diminished or abolished. 129SvEvTac (SV129) mice and Brown Norway rats (BN) served as controls. We confirmed that plasma HMW kininogen in BNK rats was 100-fold lower than in BN and 140-fold lower than in Sprague-Dawley rats (33+/-4 versus 1814+/-253 and 2397+/-302 ng/mL, P<.01). Each strain of mice was divided into (1) controls (without preconditioning); (2) one cycle of preconditioning (3 minutes ligation and 5 minutes reperfusion); and (3) three cycles of preconditioning. Each strain of rats was divided into (1) controls; and (2) three cycles of preconditioning. All animals were subjected to 30 minutes of ischemia and 120 minutes of reperfusion. In SV129 controls, the ratio of infarct size to risk area (IS/AR) was 55.6+/-4.6%. One and three cycles of preconditioning reduced IS/AR to 38.6+/-3.2% and 31.1+/-2.3%, respectively (P<.05 and P<.01 versus control). This protective effect was absent in B2-KO mice: IS/AR was 54.8+/-2.9% in controls, 58.5+/-3.6% with one cycle of preconditioning, and 58.5+/-3.4% with three cycles. In BN rats without preconditioning, IS/AR was 84.7+/-3.9%; preconditioning reduced it to 61.6+/-3.4% (P<.01). In BNK rats, IS/AR was 87.1+/-4.8% in controls and 84.3+/-4.1% with preconditioning. Preconditioning also prevented reperfusion arrhythmias in BN but not BNK rats. Within species, risk area, mean blood pressure, and heart rate were similar between strains. We concluded that (1) preconditioning protects the heart against ischemia/reperfusion injury in mice and rats; (2) activation of prekallikrein, which in turn generates kinins from HMW kininogen, may contribute to the effect of preconditioning; and (3) an intact kallikrein-kinin system is necessary for the cardioprotective effect of preconditioning.

摘要

相似文献

1
Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats.
Hypertension. 1997 Sep;30(3 Pt 2):735-40. doi: 10.1161/01.hyp.30.3.735.
2
Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats.激肽在慢性心力衰竭及激肽原缺乏大鼠中血管紧张素转换酶抑制剂治疗效果中的作用。
Am J Physiol Heart Circ Physiol. 2000 Feb;278(2):H507-14. doi: 10.1152/ajpheart.2000.278.2.H507.
3
Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation.
J Am Coll Cardiol. 1996 Nov 15;28(6):1616-22. doi: 10.1016/s0735-1097(96)00371-3.
4
Bradykinin inhibits development of myocardial infarction through B2 receptor signalling by increment of regional blood flow around the ischaemic lesions in rats.缓激肽通过B2受体信号通路增加大鼠缺血性病变周围的局部血流量,从而抑制心肌梗死的发展。
Br J Pharmacol. 2003 Jan;138(1):225-33. doi: 10.1038/sj.bjp.0705013.
5
Suppression of dextran sulfate sodium-induced colitis in kininogen-deficient rats and non-peptide B2 receptor antagonist-treated rats.激肽原缺乏大鼠和非肽B2受体拮抗剂处理大鼠中硫酸葡聚糖钠诱导的结肠炎的抑制作用。
Jpn J Pharmacol. 2002 Sep;90(1):59-66. doi: 10.1254/jjp.90.59.
6
Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats.激肽释放酶-激肽系统的慢性阻断对大鼠高血压发展的影响。
Hypertension. 2001 Jan;37(1):121-128. doi: 10.1161/01.hyp.37.1.121.
7
Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia.组织激肽释放酶在心肌缺血的缺血预处理和药物预处理的心脏保护作用中的作用。
FASEB J. 2005 Jul;19(9):1172-4. doi: 10.1096/fj.04-3508fje. Epub 2005 Apr 28.
8
Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies.激肽在心肌缺血病理生理学中的作用。体外和体内研究。
Diabetes. 1996 Jan;45 Suppl 1:S51-8. doi: 10.2337/diab.45.1.s51.
9
Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation.组织激肽释放酶通过直接激活激肽B2受体发挥心脏保护作用,而不依赖于激肽的形成。
Hypertension. 2008 Oct;52(4):715-20. doi: 10.1161/HYPERTENSIONAHA.108.114587. Epub 2008 Sep 2.
10
Cardioprotection and kallikrein-kinin system in acute myocardial ischaemia in mice.小鼠急性心肌缺血中的心脏保护与激肽释放酶-激肽系统
Clin Exp Pharmacol Physiol. 2008 Apr;35(4):489-93. doi: 10.1111/j.1440-1681.2008.04902.x.

引用本文的文献

1
Evaluation of time-dependent phenotypes of myocardial ischemia-reperfusion in mice.评价小鼠心肌缺血再灌注的时相表型。
Aging (Albany NY). 2023 Oct 10;15(19):10627-10639. doi: 10.18632/aging.205103.
2
Role of Kinins in Hypertension and Heart Failure.激肽在高血压和心力衰竭中的作用。
Pharmaceuticals (Basel). 2020 Oct 28;13(11):347. doi: 10.3390/ph13110347.
3
Autocrine Bradykinin Release Promotes Ischemic Preconditioning-Induced Cytoprotection in Bovine Aortic Endothelial Cells.自分泌缓激肽释放促进牛主动脉内皮细胞缺血预处理诱导的细胞保护作用。
Int J Mol Sci. 2020 Apr 23;21(8):2965. doi: 10.3390/ijms21082965.
4
Kallikrein/K1, Kinins, and ACE/Kininase II in Homeostasis and in Disease Insight From Human and Experimental Genetic Studies, Therapeutic Implication.激肽释放酶/K1、激肽与血管紧张素转换酶/激肽酶II在稳态及疾病中的作用:来自人类和实验性遗传学研究的见解及治疗意义
Front Med (Lausanne). 2019 Jun 27;6:136. doi: 10.3389/fmed.2019.00136. eCollection 2019.
5
Modulation of cardiac vagal tone by bradykinin acting on nucleus ambiguus.血管舒缓激肽通过作用于疑核调制心脏迷走神经张力。
Neuroscience. 2017 Dec 4;365:23-32. doi: 10.1016/j.neuroscience.2017.09.034. Epub 2017 Sep 23.
6
A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.基于新发展理念的治疗盐敏感性高血压的新型抗高血压药物类别
Pharmaceuticals (Basel). 2010 Jan 7;3(1):59-109. doi: 10.3390/ph3010059.
7
In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases.对肽酶敏感性各异的缓激肽B2受体激动剂的体内效应
Front Pharmacol. 2016 Jan 12;6:306. doi: 10.3389/fphar.2015.00306. eCollection 2015.
8
The kallikrein-kinin system as a regulator of cardiovascular and renal function.激肽释放酶-激肽系统作为心血管和肾功能的调节剂。
Compr Physiol. 2011 Apr;1(2):971-93. doi: 10.1002/cphy.c100053.
9
Bradykinin type-2 receptor expression correlates with age and is subjected to transcriptional regulation.缓激肽2型受体表达与年龄相关,并受到转录调控。
Int J Vasc Med. 2012;2012:159646. doi: 10.1155/2012/159646. Epub 2011 Oct 3.
10
Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia.遗传决定的血管紧张素转换酶水平与心肌对缺血的耐受性。
FASEB J. 2010 Dec;24(12):4691-700. doi: 10.1096/fj.10-165902. Epub 2010 Jul 28.